Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?

Abstract : Lung cancer is the major cause of death from cancer in the world and its incidence is increasing in women. Despite the progress made in developing immunotherapies and therapies targeting genomic alterations, improvement in the survival rate of advanced stages or metastatic patients remains low. Thus, urgent development of effective therapeutic molecules is needed. The discovery of novel therapeutic targets and their validation requires high quality biological material and associated clinical data. With this aim, we established a biobank dedicated to lung cancers. We describe here our strategy and the indicators used and, through an overall assessment, present the strengths, weaknesses, opportunities and associated risks of this biobank.
Type de document :
Article dans une revue
Liste complète des métadonnées

Littérature citée [76 références]  Voir  Masquer  Télécharger

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01834086
Contributeur : Laurent Jonchère <>
Soumis le : jeudi 18 juillet 2019 - 15:36:30
Dernière modification le : mercredi 14 août 2019 - 16:02:09

Fichier

cancers-10-00220-v2.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Citation

Kevin Washetine, Simon Heeke, Christelle Bonnetaud, Mehdi Kara-Borni, Marius Ilié, et al.. Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?. Cancers, MDPI, 2018, 10 (7), pp.E220. ⟨10.3390/cancers10070220⟩. ⟨hal-01834086⟩

Partager

Métriques

Consultations de la notice

57

Téléchargements de fichiers

52